| Message: | Product Name Bivalirudin Trifluoroacetate
Sequence D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH
Cas No. 128270-60-0
Molecular Formula C98H138N24O33
Molecular Weight 2180.33
Purity (HPLC) 98.0%min.
Appearance? White Powder
Single Impurity (HPLC)? 1.0%max
Amino Acid Composition? ±10% of theoretical
Peptide Content (N%) ≥80.0%
Water Content (Karl Fischer)? ≤8.0%
TrifluoroAcetate Content(HPIC) ≤12.0%
MS (ESI) Consistent
Mass Balance? 95.0~105.0%
2. Description:
Bivalirudin (Angiomax or Angiox, manufactured by The Medicines Company) is a specific and reversible direct thrombin inhibitor (DTI).
Bivalirudin is a DTI that overcomes many limitations seen with indirect thrombin inhibitors, such as heparin. Bivalirudin is a short, synthetic peptide that is potent, highly specific, and a reversible inhibitor of thrombin. It inhibits both circulating and clot-bound thrombin, while also inhibiting thrombin-mediated platelet activation and aggregation. Bivalirudin has a quick onset of action and a short half-life. It does not bind to plasma proteins (other than thrombin) or to red blood cells. Therefore it has a predictable antithrombotic response. There is no risk for Heparin Induced Thrombocytopenia/Heparin Induced Thrombosis-Thrombocytopenia Syndrome (HIT/HITTS). It does not require a binding cofactor such as antithrombin and does not activate platelets. These characteristics make bivalirudin an ideal alternative to heparin.
Bivalirudin clinical studies demonstrated consistent positive outcomes in patients with stable angina, unstable angina (UA), non-ST segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI) undergoing PCI in 7 major randomized trials.
3. Application:
|
my account
